Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% 3-Year EBITDA Growth Rate is 92.90% as of Sep. 2025, which is at its 10-year median of 92.90. The stock has 2 warning signs investors should review. Among 1,135 Biotechnology companies, Windtree Therapeutics ranks better than 98.33% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 92.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Windtree Therapeutics was 92.90% per year. The lowest was 92.90% per year. And the median was 92.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Windtree Therapeutics 3-Year EBITDA Growth Rate Related Terms
WINT vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Windtree Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 92.90% mean?
Windtree Therapeutics (WINT) has a 3-Year EBITDA Growth Rate of 92.90% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Windtree Therapeutics and its competitors. This is near median its historical median of 92.90. Over the past decade, Windtree Therapeutics' 3-Year EBITDA Growth Rate has ranged from 92.90 to 92.90. According to the industry distribution chart, Windtree Therapeutics ranks #19 out of 1135 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Windtree Therapeutics' 3-Year EBITDA Growth Rate too high?
Windtree Therapeutics' current 3-Year EBITDA Growth Rate of 92.90% is near median its 10-year median of 92.90. Over the past 10 years, this metric has ranged from a low of 92.90 to a high of 92.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Windtree Therapeutics' value of 92.90% is 523.5% above this industry median. Based on the distribution chart, Windtree Therapeutics ranks #19 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Windtree Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #19 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Windtree Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Windtree Therapeutics' value of 92.90% is 523.5% above this benchmark. Historically, Windtree Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 92.90 to 92.90 over the past decade. While the company's 10-year median is 92.90 vs. the industry median of 14.90, Windtree Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windtree Therapeutics's current 3-Year EBITDA Growth Rate of 92.90% is 523.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Windtree Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current 3-Year EBITDA Growth Rate is 92.90%, which is near median its own 10-year median of 92.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current 3-Year EBITDA Growth Rate of 92.90%. The current 3-Year EBITDA Growth Rate is 92.90%, which is near median its 10-year median of 92.90 and 523.5% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current 3-Year EBITDA Growth Rate is 92.90% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
